PLYMOUTH MEETING, Pa., Aug. 31, 2011 /PRNewswire/ — BioBDx
announced today that the Company’s Chairman and CEO Byron Hewett
will present at the 2011 BioPharm America Conference taking place
September 7-9.  BioBDx manufactures and markets the
Quotient® System, a tool that objectively measures brain
functions related to deficits in response inhibition. The
first FDA-cleared application of this platform technology is
objective measurement of hyperactivity, impulsivity and inattention
as an aid in the assessment of attention-deficit hyperactivity
disorder (ADHD).  Mr. Hewett will provide a company overview
and update on the Quotient ADHD System on Thursday, September 8 at
4:15 p.m. EDT in the Otis room at the Westin Boston Waterfront
Hotel in Boston, MA.

About the Quotient® ADHD TestThe Quotient® ADHD Test
measures motion and analyzes shifts in attention state to give an
objective picture of the core symptom areas of ADHD.
 Clinicians use the Quotient® ADHD Test at the initial
visit to assess severity of the three core symptoms of ADHD;
hyperactivity, inattention and impulsivity.  Patients may be
re-assessed periodically at follow-up visits to guide treatment
plans.  The clinician integrates the Quotient® ADHD Test
report with information from other assessment tools and the
clinical evaluation to help guide the discussion on the treatment
plan. For more information about the Quotient® ADHD System,
please visit http://www.biobdx.com/products

About BioBehavioral Diagnostics CompanyBioBDx manufactures
and markets the Quotient System, a tool that aids in the objective
and accurate assessment of neural control functions related to
deficits in inhibitory control.  We are dedicated to providing
physicians, parents and patients with high-value information to
guide personalized strategies and to enhance quality of life for
patients with ADHD. &

‘/>”/>

SOURCE